Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term topotecan. Found 12 abstracts

Adams SF, Marsh EB, Elmasri W, Halberstadt S, VanDecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC, Belsadron G, Biochimie V P. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecologic Oncology. 2011 Dec;123(3):486-91.   PMCID: PMC3260049
Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, Lee J, Fu LW, Chen ZS. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochemical pharmacology. 2010 Jan;79(2):154-61.   PMCID: PMC2953260
Rose PG, Tian CQ, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2010 May;117(2):324-9.   PMCID: NIH funded - needs PMCID
Bookman MA, McMeekin DS, Fracasso PM. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group. Gynecologic Oncology. 2006 Nov;103(2):473-8.
Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology. 2005 Jan;96(1):67-71.
Treat J, Huang CH, Lane SR, Levin J. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. The oncologist. 2004 Jan;9(2):173-81.
Stevenson JP, DeMaria D, Sludden J, Kaye SB, Paz-Ares L, Grochow LB, McDonald A, Selinger K, Wissel P, O'Dwyer PJ, Twelves C. Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Annals of Oncology. 1999 Mar;10(3):339-44.
Paz-Ares L, Kunka R, DeMaria D, Cassidy J, Alden M, Beranek P, Kaye S, Littlefield D, Reilly D, Depee S, Wissel P, Twelves C, O'Dwyer P. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. British Journal of Cancer. 1998 Nov;78(10):1329-36.
Stevenson JP, Scher RM, Kosierowski R, Fox SC, Simmonds M, Yao KS, Green F, Broom C, Fields SZ, Krebs JB, O'Dwyer PJ. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. European Journal of Cancer. 1998 Aug;34(9):1358-62.
Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF, McAleer CA, Giantonio BJ. Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Investigational New Drugs. 1995 Jan;13(3):235-40.
Scher RM, Kosierowski R, Lusch C, Alexander R, Fox S, Redei I, Green F, Raskay B, Amfoh K, Engstrom PF, Odwyer PJ. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Investigational New Drugs. 1995 Jan;13(4):347-54.
Odwyer PJ, Lacreta FP, Haas NB, Halbherr T, Frucht H, Goosenberg E, Yao KS. Clinical, Pharmacokinetic and Biological Studies of Topotecan. Cancer Chemotherapy and Pharmacology. 1994 Aug;34:S46-S52.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term topotecan

topotecan chemotherapy camptothecin trial inhibitor cancer CHEMOTHERAPY carcinoma cell lung-cancer CARCINOMA paclitaxel infusion cpt-11 tumors topoisomerase I continuous infusion pharmacodynamics pancreatic cancer camptothecin analogues GG211 ovarian cancer xenografts dna topoisomerase-i critical reassessment efficacy PACLITAXEL cells resistance BRCA mutations GI147211 Disease control cell-lung-cancer therapy pain immunogenicity gemcitabine cell death abcc10 antitumor-activity peritoneal carcinoma doxorubicin dna untwisting enzyme EGFR Tyrosine kinase inhibitor-Lapatinib-Erlotinib-ABC transporters-MRP7 colony-stimulating factor line gefitinib 100880 survival phase-ii breast-cancer continuous subfamily-b member-1 stage-iii ETOPOSIDE 9-aminocamptothecin topoisomerase i expression primary peritoneal carcinoma KeyWords Plus: Survival VINCRISTINE VITRO PHASE-III responses gene expression phase II study TRIAL phase I pegylated liposomal Progression-free Multidrug resistance ABCC10 solid tumors topoisomerase-i inhibitor DOXORUBICIN palliative care phase II trial CISPLATIN disease lung-cancer topoisomerase I inhibitors protein phase I trial STAGE-III INFUSION nsc- 5-fluorouracil prostate gi147211 carboplatin CYCLOPHOSPHAMIDE analogs inhibitors platinum PROGNOSTIC FACTORS sequential camptothecin analogs pharmacokinetics Ovarian cancer Doxil therapy cancer-patients doublets salvage therapy Ovarian carcinoma DOUBLETS transporters Platinum-resistant phase-i oophorectomy IRRADIATION cisplatin phase-ii trial topoisomerase-i THERAPY drug-resistance lung neoplasms platinum-refractory ovarian RECURRENT laparotomy Response
Last updated on Wednesday, February 05, 2020